(3S,5R)-2,5-dimethylhept-6-en-3-ol | 1417175-80-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3S,5R)-2,5-dimethylhept-6-en-3-ol
• CAS: 1417175-80-4
• 化学式: C₉H₁₈O
• 分子量: 142.241
• InChiKey: UHAZCWRQDRFZLX-IUCAKERBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  在 sodium periodate 、 二氯苯酚溴酯 、 potassium carbonate 作用下， 以 二氯甲烷 为溶剂， 反应 50.0h， 生成 (3S,5R)-2,5-dimethylhept-6-en-3-ol
  参考文献：
  名称：

  Enantioselective Homocrotylboration of Aliphatic Aldehydes

  摘要：

  A practical route to optically pure syn-homocrotylation reagents is described, including highly diastereo- and enantioselective preparation of numerous syn-homocrotyl products, as well as several matched mismatched pairs. NMR experiments suggest that the active homocrotylating species is a cyclopropylcarbinyldichloroborane generated by chloride exchange from the PhBCl2 activator. Computational studies support the intermediacy of chloroboranes and suggest that homoallyl/homocrotyl transfers occur through Zimmerman-Traxler transition states.

  DOI：

  10.1021/ja311061n

文献信息

• [EN] COMPOUNDS THAT INHIBIT MCL-1 PROTEIN<br/>[FR] COMPOSÉS INHIBANT LA PROTÉINE MCL-1
  申请人：AMGEN INC

  公开号：WO2017147410A1

  公开（公告）日：2017-08-31

  Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

  本文提供了髓样细胞白血病1蛋白（Mcl-1）抑制剂，其制备方法，相关的药物组合物，以及使用这些物质的方法。例如，本文提供了化合物I的公式，及其药用盐和含有这些化合物的药物组合物。本文提供的化合物和组合物可以用于治疗癌症等疾病或症状。
• Enantioselective <i>syn</i> and <i>anti</i> Homocrotylation of Aldehydes: Application to the Formal Synthesis of Spongidepsin
  作者：Hongkun Lin、Leiming Tian、Isaac J. Krauss

  DOI：10.1021/jacs.5b08858

  日期：2015.10.14

  Whereas crotylboration has been a useful method for synthesis of stereochemically complex products, we have shown that homocrotylboration can be achieved with cyclopropanated crotylation reagents, and that the stereo-selectivity of the reaction can be predicted by analogous models. This paper presents a full account of this work, including the first examples of asymmetric anti homocrotylation. The scope of this reaction is demonstrated with highly enantioselective homocrotylation of both aliphatic and aromatic aldehydes, as well as double diastereoselection studies. An application of the synthesis of the marine natural product spongidepsin is presented, as well as streamlined syntheses of homocrotylation reagents.
• Boron Carboxylate Catalysis of Homoallylboration
  作者：Gabrielle J. Dugas、Yu-hong Lam、K. N. Houk、Isaac J. Krauss

  DOI：10.1021/jo500599h

  日期：2014.5.16

  Boron tris(trifluoroacetate) is identified as the first effective catalyst for the homoallyl- and homocrotylboration of aldehydes by cyclopropylcarbinylboronates. NMR spectroscopic studies and theoretical calculations of key intermediates and transition states both suggest that a ligand-exchange mechanism, akin to our previously reported PhBCl2-promoted homoallylations, is operative. Our experimental and theoretical results also suggest that the catalytic activity of boron tris(trifluoroacetate) might originate from more facile catalytic turnover of the trifluoroacetate ligands (in agreement with DFT calculations) or from a lower propensity for formation of off-pathway reservoir intermediates (as observed by H-1 NMR). This work shows that carboxylates are viable catalytic ligands for homoallyl- and homocrotylations of carbonyl compounds and opens the door to the development of catalytic asymmetric versions of this transformation.
• COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
  申请人：AMGEN INC.

  公开号：US20210230189A1

  公开（公告）日：2021-07-29

  Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.